Anti-IL-17α (Secukinumab), Human IgG1 Antibody
In vitro studies
Recombinant
Human
IgG1, kappa
Monoclonal
Human IL-17α
- Data sheet: View or download
The research-grade biosimilar is a human IgG1 monoclonal antibody that targets IL-17α and prevents its association with the receptor IL-17R. This results in decreased release of proinflammatory cytokines and chemokines and downregulation of inflammation. IL-17 represents a family of cytokines (IL-17 A-F) that is released by T-helper-17 (Th17) cells, mast cells, neutrophils, and dendritic cells and promotes inflammation. Studies show that IL-17 is associated with multiple autoimmune diseases such as rheumatoid arthritis, spondyloarthritis, psoriasis, Crohn's disease, and multiple sclerosis. The original monoclonal antibody received approval from the FDA to treat plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
-80°C